The estimated Net Worth of Cheryl Pegus is at least $14.9 Milion dollars as of 16 December 2020. Cheryl Pegus owns over 31,147 units of Phreesia Inc stock worth over $391,193 and over the last 8 years he sold PHR stock worth over $13,981,429. In addition, he makes $503,902 as Independent Director at Phreesia Inc.
Sign up
Cheryl Pegus PHR stock SEC Form 4 insiders trading
Cheryl has made over 3 trades of the Phreesia Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 31,147 units of PHR stock worth $1,741,429 on 16 December 2020.
The largest trade he's ever made was selling 500,000 units of Phreesia Inc stock on 17 December 2019 worth over $12,240,000. On average, Cheryl trades about 29,564 units every 61 days since 2016. As of 16 December 2020 he still owns at least 16,775 units of Phreesia Inc stock.
You can see the complete history of Cheryl Pegus stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cheryl Pegus biography
Dr. Cheryl Pegus M.D. is Independent Director of the Company. Dr. Pegus currently serves as Chief Medical Officer and Senior Vice President of Health Care Services for Cambia Health Solutions, Inc., a position she has held since 2018. Previously, Dr. Pegus was President of Caluent LLC, a health care data analytics company, from 2013 to 2018 and a Clinical Professor of Medicine and Population Health at NYU Langone Medical Center from 2014 to 2017. Prior to that, Dr. Pegus served as the first Chief Medical Officer of Walgreen Co.’s health care services, product launches and data analytics unit, from 2010 to 2013. Dr. Pegus currently serves as Chair of the Board of the Association of Black Cardiologists and as a board member of Tactile Systems Technology, Inc. and US Acute Care Solutions, LLC. Dr. Pegus earned her B.A. degree from Brandeis University in Waltham, Massachusetts, her M.D. from Weill Cornell Medical College in New York, New York and her Master’s in public health from Columbia University Mailman School of Public Health in New York, New York. Pegus’ experience as a physician and her background in the healthcare industry make her qualified to serve on our Board.
What is the salary of Cheryl Pegus?
As the Independent Director of Phreesia Inc, the total compensation of Cheryl Pegus at Phreesia Inc is $503,902. There are 6 executives at Phreesia Inc getting paid more, with Chaim Indig having the highest compensation of $10,474,400.
How old is Cheryl Pegus?
Cheryl Pegus is 56, he's been the Independent Director of Phreesia Inc since 2019. There are 4 older and 12 younger executives at Phreesia Inc. The oldest executive at Phreesia Inc is Mark Smith, 68, who is the Independent Director.
What's Cheryl Pegus's mailing address?
Cheryl's mailing address filed with the SEC is 300 BOSTON SCIENTIFIC WAY, , MARLBOROUGH, MA, 01752-1234.
Insiders trading at Phreesia Inc
Over the last 5 years, insiders at Phreesia Inc have traded over $277,935,884 worth of Phreesia Inc stock. The most active insiders traders include Edward L Cahill, Venture Partners Ii, L.P.Hl... oraz Scott Perricelli. On average, Phreesia Inc executives and independent directors trade stock every 8 days with the average trade being worth of $1,320,099. The most recent stock trade was executed by Allison C Hoffman on 26 August 2024, trading 14,110 units of PHR stock currently worth $367,283.
What does Phreesia Inc do?
leading healthcare organizations choose phreesia to revolutionize their point of service. in medical groups of all sizes, phreesia’s flexible and scalable platform drives tangible results across administrative, financial and clinical operations so that staff can focus on providing exceptional patient care.
What does Phreesia Inc's logo look like?
Complete history of Cheryl Pegus stock trades at Tactile Systems Technology Inc, Boston Scientific oraz Phreesia Inc
Phreesia Inc executives and stock owners
Phreesia Inc executives and other stock owners filed with the SEC include:
-
Chaim Indig,
Chief Executive Officer, Director -
Evan Roberts,
Chief Operating Officer -
Thomas Altier,
Chief Financial Officer -
Chaim Indig,
Co-Founder, CEO & Director -
David Linetsky,
Sr. VP of Life Sciences -
Gillian Munson,
Independent Director -
Cheryl Pegus,
Independent Director -
Charles Kallenbach,
General Counsel, Secretary -
Michael Weintraub,
Independent Chairman of the Board -
Allison C. Hoffman,
Gen. Counsel & Sec. -
Mark Smith,
Independent Director -
Edward Cahill,
Independent Director -
Lainie Goldstein,
Director -
Dusty Lieb,
Director -
Balaji Gandhi,
Vice President - Investor Relations -
Daniel Nathan,
Chief Technology Officer -
David Linetsky,
Senior Vice President - Life Sciences -
Amy VanDuyn,
Senior Vice President - Human Resources -
Michael Davidoff,
Senior Vice President - Marketing and Business Development -
Randy Rasmussen,
Chief Accounting Officer -
Amy Beth VanDuyn,
Sr. VP of HR -
Michael J. Davidoff,
Sr. VP of Marketing & Bus. Devel. -
Maureen McKinney,
VP of Corp. Communications -
Daniel Nathan,
Chief Technology Officer -
Randy Rasmussen,
Chief Financial Officer -
Ramin Sayar,
Director -
Venture Partners Ii, L.P.Hl...,
-
Lisa Egbuonu Davis,
Director -
Venture Management Co. V, L...,
-
Scott Perricelli,
Director -
Capital Iv, Llcllr Equity P...,
-
Yvonne Hui,
Principal Accounting Officer -
Allison C Hoffman,
General Counsel & Secretary -
Janet Gunzburg,
Principal Accounting Officer